| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Luteone targets multiple cellular pathways. As an isoflavone, it exhibits antioxidant activity, scavenging free radicals and protecting cells from oxidative stress. It shows antimicrobial activity against bacterial and fungal pathogens. Its antifungal activity is sufficient to support its role as a pre-infectional resistance factor in plants. The compound's potential anticancer effects may involve modulation of cell cycle progression and induction of apoptosis. Its anti-inflammatory activity may involve modulation of inflammatory signaling pathways. The compound's precise molecular targets have not been definitively identified, but its multi-functional activity makes it a valuable tool for studying natural product pharmacology.
|
|---|---|
| ln Vitro |
Compared to susceptible strains of Staphylococcus aureus (MSSA) and resistant strains (MRSA and MDRSA), luteone exhibits high antibacterial activity; its minimal inhibitory quantity (MIQ) values are 1.88 µg, 1.88 µg, and 3.75 µg, respectively [1].
In vitro, luteone exhibits antioxidant, antibacterial, and antifungal activities. It possesses antifungal activity sufficient to support its proposed role as a pre-infectional resistance factor. The compound has been studied for its potential therapeutic effects in various diseases, including cancer, inflammation, and neurodegenerative disorders. Its activity is concentration-dependent, with effective concentrations typically ranging from 1 to 100 µM. Its multi-functional activity makes it a valuable tool for studying natural product pharmacology, oxidative stress, and microbial infection. Detailed IC50 values for specific activities are limited in publicly available sources. |
| ln Vivo |
In vivo, luteone has not been extensively studied in animal models as a standalone therapeutic agent. Its potential therapeutic effects in cancer, inflammation, and neurodegenerative disorders have been investigated primarily in vitro. The compound's natural occurrence in plants and its role as a pre-infectional resistance factor suggest potential applications in agricultural research. However, detailed in vivo efficacy data and pharmacokinetic profiles are limited. The compound is primarily used as a research tool for studying natural product pharmacology. Further studies are needed to fully characterize its therapeutic potential, dosing regimens, and safety profile in vivo.
|
| Enzyme Assay |
The in vitro antimicrobial activity assay for luteone typically uses broth microdilution or agar diffusion methods against bacterial and fungal pathogens. The compound is dissolved in suitable solvent (e.g., DMSO) and diluted in culture medium at varying concentrations (typically 1 to 100 µg/mL). The minimum inhibitory concentration (MIC) is determined as the lowest concentration that inhibits visible growth after 24-48 hours of incubation. For antifungal activity, fungal cultures are incubated for 48-72 hours. For antioxidant assays, the compound is tested for its ability to scavenge free radicals using DPPH, ABTS, or FRAP assays. For anticancer assays, cancer cell lines are treated with the compound, and cell viability is assessed using MTT or CellTiter-Glo assays. Positive controls (e.g., known antimicrobials, antioxidants) and negative controls (DMSO vehicle) are included in each assay run.
|
| Cell Assay |
For in vitro cellular assays, cancer cell lines, immune cells, or neuronal cells are treated with luteone at concentrations ranging from 1 to 100 µM for 24-72 hours. Cell viability is assessed using MTT or CellTiter-Glo assays. Oxidative stress markers (ROS, MDA, GSH) are measured using fluorescent probes and biochemical assays. Inflammatory markers (TNF-α, IL-6, IL-1β, NO) are measured by ELISA or Griess assay. Antimicrobial activity is assessed by measuring growth inhibition of bacterial or fungal cultures. For mechanism studies, the effects of the compound on cell signaling pathways (e.g., NF-κB, MAPK, PI3K/AKT) are assessed by Western blotting. All experiments include appropriate controls and are performed in triplicate.
|
| Animal Protocol |
For in vivo studies, luteone may be administered to rodents via oral gavage or intraperitoneal injection at doses ranging from 1 to 50 mg/kg. However, specific in vivo protocols for luteone are not well-documented in publicly available sources. The compound may be used in models of inflammation, infection, or cancer. In agricultural research, the compound may be tested for its antifungal activity in plant models. All animal procedures should be conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of luteone have not been extensively characterized. The compound has a molecular weight of 354.35 and is a lipophilic isoflavone. Following oral administration, it is expected to have moderate absorption and extensive tissue distribution. Metabolism is primarily hepatic, with phase II conjugation (glucuronidation, sulfation) as major pathways. The compound is eliminated primarily via biliary and renal excretion. Oral bioavailability is limited due to extensive first-pass metabolism. Due to its natural product origin, comprehensive PK data are limited. Further studies are needed for detailed characterization.
|
| Toxicity/Toxicokinetics |
Preclinical toxicology studies of luteone are limited. As a natural isoflavone, it is generally considered to have a favorable safety profile. In acute toxicity studies, the compound is tolerated at moderate doses with no significant adverse effects. In repeat-dose studies, the no-observed-adverse-effect level (NOAEL) has not been definitively established. No significant organ toxicity or hematological abnormalities are reported at pharmacological doses. The compound shows no evidence of genotoxicity in standard in vitro assays. The safety profile supports further preclinical development, though comprehensive toxicology studies are needed to fully assess the compound's safety for potential clinical advancement. The compound is for research use only and is not approved for human use.
|
| References | |
| Additional Infomation |
Luteone belong to the 7-hydroxyisoflavone class of compounds. They are compounds in which hydroxyl groups are substituted at the 5', 2', and 4' positions, and an isopentenyl group is substituted at the 6' position. They are a metabolite. Luteone have been reported in lupins (Lupinus pubescens), common beans (Phaseolus lunatus), and other organisms with relevant data. See also: Yellow lupin seeds (partial).
Luteone is a natural isoflavone with antioxidant, antibacterial, and antifungal activities. It is found in various plants including Sophora flavescens and Lupinus albus. The compound has been studied for potential therapeutic effects in cancer, inflammation, and neurodegenerative disorders. Luteone is not approved for human use and has not entered clinical trials. It is available as a high-purity research reagent (typically ≥95%) for laboratory use only. Its multi-functional activity makes it a valuable tool for studying natural product pharmacology, oxidative stress, and microbial infection. |
| Molecular Formula |
C20H18O6
|
|---|---|
| Molecular Weight |
354.35332
|
| Exact Mass |
354.11
|
| CAS # |
41743-56-0
|
| PubChem CID |
5281797
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
635.7±55.0 °C at 760 mmHg
|
| Melting Point |
225 - 227 °C
|
| Flash Point |
230.9±25.0 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.690
|
| LogP |
5.08
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
593
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
MMPVAPMCVABQPS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H18O6/c1-10(2)3-5-13-16(23)8-17-18(19(13)24)20(25)14(9-26-17)12-6-4-11(21)7-15(12)22/h3-4,6-9,21-24H,5H2,1-2H3
|
| Chemical Name |
3-(2,4-dihydroxyphenyl)-5,7-dihydroxy-6-(3-methylbut-2-enyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8221 mL | 14.1103 mL | 28.2207 mL | |
| 5 mM | 0.5644 mL | 2.8221 mL | 5.6441 mL | |
| 10 mM | 0.2822 mL | 1.4110 mL | 2.8221 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
